Histopathologic Characteristics of Choroidal Melanoma in Eyes Enucleated After Iodine 125 Brachytherapy in the Collaborative Ocular Melanoma Study

Authors:
  • MDMarie Diener-West
    Marie Diener-West
  • SRSandra M. Reynolds
    Sandra M. Reynolds
  • HGHans E. Grossniklaus
    Hans E. Grossniklaus
  • WGW. Richard Green
    W. Richard Green

Abstract
The Collaborative Ocular Melanoma Study (COMS) Group showed no difference in survival between patients randomized to primary enucleation compared with iodine 125 plaque brachytherapy.1,2 A potentially important subgroup of the radiotherapy arm are those patients who had secondary enucleation. Of the 650 COMS patients who received brachytherapy, the Kaplan-Meier estimate of secondary enucleation within 5 years of treatment was 12.5%.3 The clinical features of these “plaque failures” have been previously reported.3 Enucleations within the first 3 years after brachytherapy are likely due to treatment failure, and this is weakly associated with reduced survival after adjusting for other baseline variables (adjusted risk ratio, 1.5; 95% confidence interval, 0.94-2.52; P = .08).3 This study describes the histopathologic findings in eyes with failed plaques as compared with a control group with primary enucleation.

This publication has 1 reference indexed in Scilit: